Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/38843
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorHartung, Hans-Peter-
dc.contributor.authorVermersch, Patrick-
dc.contributor.authorPugliatti, Maura-
dc.contributor.authorPozzilli, Carlo-
dc.contributor.authorGrigoriadis, Nikolaos-
dc.contributor.authorAlkhawajah, Mona-
dc.contributor.authorAiras, Laura-
dc.contributor.authorLinker, Ralf-
dc.contributor.authorOreja-Guevara, Celia-
dc.date.accessioned2022-11-07T10:10:35Z-
dc.date.available2022-11-07T10:10:35Z-
dc.date.issued2022-
dc.date.submitted2022-11-04T11:02:17Z-
dc.identifier.citationFrontiers in Immunology, 13 (Art N° 991291)-
dc.identifier.urihttp://hdl.handle.net/1942/38843-
dc.description.abstractThe clinical course of multiple sclerosis (MS) is highly variable among patients, thus creating important challenges for the neurologist to appropriately treat and monitor patient progress. Despite some patients having apparently similar symptom severity at MS disease onset, their prognoses may differ greatly. To this end, we believe that a proactive disposition on the part of the neurologist to identify prognostic "red flags" early in the disease course can lead to much better long-term outcomes for the patient in terms of reduced disability and improved quality of life. Here, we present a prognosis tool in the form of a checklist of clinical, imaging and biomarker parameters which, based on consensus in the literature and on our own clinical experiences, we have established to be associated with poorer or improved clinical outcomes. The neurologist is encouraged to use this tool to identify the presence or absence of specific variables in individual patients at disease onset and thereby implement sufficiently effective treatment strategies that appropriately address the likely prognosis for each patient.-
dc.description.sponsorshipMedical writing support for the preparation of this manuscript along with the payment of publishing fees were provided by the ParadigMS Foundation. The creation and communication of educational materials by the ParadigMS Foundation is sponsored by Sanofi, Roche, and Merck.-
dc.language.isoen-
dc.publisherFRONTIERS MEDIA SA-
dc.rights2022 Van Wijmeersch, Hartung, Vermersch, Pugliatti, Pozzilli, Grigoriadis, Alkhawajah, Airas, Linker and Oreja-Guevara. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.-
dc.subject.othermultiple sclerosis-
dc.subject.otherprognosis-
dc.subject.otherclinical parameters-
dc.subject.othermagnetic resonance imaging (MRI)-
dc.subject.otherbiomarkers-
dc.subject.othertreatment-
dc.subject.otheroptical coherence tomography-
dc.subject.otherevoked potentials-
dc.titleUsing personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide-
dc.typeJournal Contribution-
dc.identifier.volume13-
local.bibliographicCitation.jcatA1-
dc.description.notesVan Wijmeersch, B (corresponding author), Univ Multiple Sclerosis Ctr, Hasselt, Belgium.; Van Wijmeersch, B (corresponding author), Noorderhart, Revalidatie & Multiple Sclerosis, Pelt, Belgium.; Van Wijmeersch, B (corresponding author), Hasselt Univ, REVAL & BIOMED, Hasselt, Belgium.-
dc.description.notesbart.vanwijmeersch@uhasselt.be-
local.publisher.placeAVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND-
local.type.refereedRefereed-
local.type.specifiedReview-
local.bibliographicCitation.artnr991291-
dc.identifier.doi10.3389/fimmu.2022.991291-
dc.identifier.pmid36238285-
dc.identifier.isi000874565800001-
local.provider.typewosris-
local.description.affiliation[Van Wijmeersch, Bart] Univ Multiple Sclerosis Ctr, Hasselt, Belgium.-
local.description.affiliation[Van Wijmeersch, Bart] Noorderhart, Revalidatie & Multiple Sclerosis, Pelt, Belgium.-
local.description.affiliation[Van Wijmeersch, Bart] Hasselt Univ, REVAL & BIOMED, Hasselt, Belgium.-
local.description.affiliation[Hartung, Hans-Peter] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Neurol, Dusseldorf, Germany.-
local.description.affiliation[Hartung, Hans-Peter] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia.-
local.description.affiliation[Hartung, Hans-Peter] Palacky Univ Olomouc, Dept Neurol, Olomouc, Czech Republic.-
local.description.affiliation[Vermersch, Patrick] Univ Lille, Ctr Hospitalier Univ CHU Lille, Inserm LilNCog U1172, Federat Hosp Univ FHU Precise, Lille, France.-
local.description.affiliation[Pugliatti, Maura] Univ Ferrara, Dept Neurosci & Rehabil, Ferrara, Italy.-
local.description.affiliation[Pugliatti, Maura] San Anna Univ Hosp, Unit Clin Neurol, Ferrara, Italy.-
local.description.affiliation[Pozzilli, Carlo] Sapienza Univ, Dept Human Neurosci, Rome, Italy.-
local.description.affiliation[Grigoriadis, Nikolaos] Aristotle Univ Thessaloniki, B Dept Neurol, Thessaloniki, Greece.-
local.description.affiliation[Alkhawajah, Mona] King Faisal Specialist Hosp & Res Ctr, Neurosci Ctr, Res Ctr, Riyadh, Saudi Arabia.-
local.description.affiliation[Airas, Laura] Univ Turku, Turku Univ Hosp, Turku, Finland.-
local.description.affiliation[Linker, Ralf] Univ Hosp Regensburg, Dept Neurol, Regensburg, Germany.-
local.description.affiliation[Oreja-Guevara, Celia] Hosp Clin San Carlos, Inst Invest Sanitaria Hosp Cliin San Carlos IDISSC, Dept Neurol, Madrid, Spain.-
local.description.affiliation[Oreja-Guevara, Celia] Univ Complutense Madrid, Fac Med, Dept Med, Madrid, Spain.-
local.uhasselt.internationalyes-
item.validationecoom 2023-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorHartung, Hans-Peter-
item.contributorVermersch, Patrick-
item.contributorPugliatti, Maura-
item.contributorPozzilli, Carlo-
item.contributorGrigoriadis, Nikolaos-
item.contributorAlkhawajah, Mona-
item.contributorAiras, Laura-
item.contributorLinker, Ralf-
item.contributorOreja-Guevara, Celia-
item.accessRightsOpen Access-
item.fullcitationVAN WIJMEERSCH, Bart; Hartung, Hans-Peter; Vermersch, Patrick; Pugliatti, Maura; Pozzilli, Carlo; Grigoriadis, Nikolaos; Alkhawajah, Mona; Airas, Laura; Linker, Ralf & Oreja-Guevara, Celia (2022) Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide. In: Frontiers in Immunology, 13 (Art N° 991291).-
item.fulltextWith Fulltext-
crisitem.journal.issn1664-3224-
crisitem.journal.eissn1664-3224-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Using personalized prognosis in the treatment of relapsing multiple sclerosis_ A practical guide.pdfPublished version445.41 kBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

6
checked on Apr 30, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.